Dr. John A. Wells III, MD
Ophthalmology (Ophthalmology Physician)
124 Sunset Court
West Columbia, SC 29169
Who else practices at this address →
Lexington County includes mental health (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 922
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Emory University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
SC license 15565 -
Retina Specialist (Ophthalmology) Physician
SC license 15565
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prisma Health Baptist Columbia, SC
Medical groups
- Palmetto Retina Center LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 922
- Services billed
- 49,523
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,840 | 49 |
| Imaging of retina | 3,110 | 885 |
| Injection, ranibizumab, 0.1 mg | 3,065 | 110 |
| Injection, aflibercept, 1 mg | 2,480 | 222 |
| Injection of drug into eye | 2,164 | 408 |
| Established patient problem focused exam of visual system | 1,318 | 524 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 855 | 27 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 854 | 35 |
| Established patient complete exam of visual system | 365 | 315 |
| Unclassified drugs | 203 | 57 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in West Columbia, SC | 157 |
| Brimonidine Tartrate Other prescribers in West Columbia, SC | 67 |
| Timolol Maleate Other prescribers in West Columbia, SC | 37 |
| Ofloxacin Other prescribers in West Columbia, SC | 35 |
| Atropine Sulfate | 30 |
| Simbrinza (brinzolamide/brimonidine tart) Other prescribers in West Columbia, SC | 22 |
| Dorzolamide Hcl Other prescribers in West Columbia, SC | 22 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in West Columbia, SC | 17 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in West Columbia, SC | 15 |
| Bromfenac Sodium | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 21 payments worth $722 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $247 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $236 |
| Astellas Pharma US Inc | $124 |
| AbbVie Inc. | $52.35 |
| Genentech USA, Inc. | $43.34 |
| Genentech, Inc. | $18.50 |
| Food and Beverage | $722 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 2 companies. The companies reported $440,817 in research payments for these studies, mostly to the institutions running them.
- Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - A phase iii study to investigate RO7200220 in patients with uveitic macular edema
Genentech, Inc. - Faricimab DME Long Term Extension Rhone X
Genentech, Inc. - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD
Genentech, Inc. - Port Delivery System for Ranibizumab
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - IAMD Observational Study
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.